VPT:CC - Ventripoint's Next Generation AI-powered Heart-scanning Technology Submitted to U.S Food and Drug Administration

(TheNewswire)

• VMS+4.0 submitted to FDA on May 1 forclearance

• Ventripoint will market new advancesafter FDA clearance

Toronto, Ontario – TheNewswire - May 6, 2024 -Ventripoint Diagnostics Ltd. (" Ventripoint " orthe " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) has reached another development milestone bysubmitting its next generation of software, VMS+4.0, to the U.S. Foodand Drug Administration (“FDA”) .

This latest advance of Ventripoint’s AI-poweredtechnology, which rapidly processes ultrasound images of the heart togenerate MRI-quality measurements of all four cardiac chambers, willseamlessly integrate into the workflow of hospitals, clinics andcaregivers.

The advances achieved by VMS+4.0 means Ventripoint’sheart-scanning technology will now offer:

• Novel presentation of full cardiac motion of all four3D reconstructed chambers of the heart through the cardiac cycle.

• Automated plotting of key anatomical landmarks of theheart, removing the need for manual inputs and providing greaterconfidence in the analysis. This provides greater reliability,consistency and reproducibility of the volumetricmeasurements.

• Increased analysis speed, making heart images availablein minutes, not the hours needed for MRI imaging.

• Full-scope use — meaning newborns to adults can beeasily scanned and assessed.

• Magnet-free sensors, reducing procedure time byeliminating a calibration procedure.

• Interfaced with any ultrasound machine withinminutes.

• Enhanced visualization tools including strain and heatmaps.

• Breakthrough vector-motion technology to show the wallmovement of the different chambers of the heart. This provides a noveland unique way of visualizing the motion of the heart includingtwist.

“It has taken our team two years of research anddevelopment to reach this major milestone,” said Ventripoint InterimCEO, Hugh MacNaught. “With VMS+4.0, we will now be offering theworld’s hospitals one of the simplest, most effective, non-invasiveheart-imaging tools in the market.”

Ventripoint submitted VMS+4.0 for clearance by FDA onMay 1, a requirement for significant software and hardware updates anddiagnostic advances. We are also pursuingregulatory clearance in other key markets such as the E.U., U.K andCanada to make this newest version of Ventripoint available to theglobal community. Ventripoint’s currentscanning technology has already received FDA, Health Canada andsimilar regulatory approvals in the United Kingdom and the EuropeanUnion, and is being used by leading hospitals in the U.S., E.U., U.K.and Canada.”

About Ventripoint DiagnosticsLtd.

Ventripoint is an industry leaderin the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary Knowledge Based Reconstruction technology, which is theresult of a decade of development and providesaccurate volumetric cardiac measurements equivalent to MRI. Thisaffordable, gold-standard alternative allows cardiologists greaterconfidence in the management of their patients. Providing better careto patients serves as a springboard and basic standard for all ofVentripoint's products that guide our future developments. Inaddition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe, and Canada.

For further information, pleasecontact:

Jonathan Robinson

JRobinson@oakhillfinancial.ca

416-669-1001

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.

Copyright (c) 2024 TheNewswire - All rights reserved.